Kathryn E Burns1, Ottiniel Chavani2, Soo Hee Jeong1, John A Duley3, David Porter4, Michael Findlay4,5, R Matthew Strother6, Nuala A Helsby7. 1. Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. 2. Canterbury Health Laboratories, Christchurch, New Zealand. 3. School of Pharmacy, University of Queensland, Brisbane, Australia. 4. Cancer and Blood, Auckland City Hospital, Grafton, Auckland, New Zealand. 5. Cancer Trials New Zealand, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. 6. Department of Oncology, Canterbury District Health Board and Department of Medicine, University of Otago, Christchurch, New Zealand. 7. Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. n.helsby@auckland.ac.nz.
Abstract
PURPOSE: Standard dosages of fluoropyrimidine chemotherapy result in severe toxicity in a substantial proportion of patients, however, routine pre-therapeutic toxicity prediction remains uncommon. A thymine (THY) challenge test can discriminate risk of severe gastrointestinal toxicity in patients receiving fluoropyrimidine monotherapy. We aimed to measure endogenous plasma uracil (U) and its ratio to dihydrouracil (DHU), and assess the performance of these parameters compared with the THY challenge test to evaluate risk of severe toxicity. METHODS: Plasma samples, previously collected from 37 patients receiving 5-fluorouracil (5-FU) or capecitabine monotherapy for a THY challenge test (ACTRN12615000586516; retrospectively registered), were assessed for endogenous plasma concentrations of U and DHU using a validated LC-MS/MS method. Renal function was estimated from blood creatinine, and patients with ≥ grade 3 toxicity (CTCAE v4.0) were classified as cases. RESULTS: There were no differences in median endogenous U plasma concentrations or U/DHU ratios between severe toxicity cases and non-cases. Significant differences between cases and non-cases were noted when these measures were normalised to the estimated renal function (CrCL), Unorm p = 0.0004; U/DHUnorm p = 0.0083. These two parameters had a sensitivity of 29%, compared with 57% for the THY challenge test in the same patients. Genotyping for clinically relevant DPYD variants was inferior to either of these pyrimidine phenotyping tests (sensitivity of 14%). CONCLUSIONS: The endogenous uracil-based parameters, adjusted to CrCL, were more predictive of increased risk of severe fluoropyrimidine toxicity than DPYD genotyping. However, endogenous U measurement detected fewer cases of severe toxicity than the THY challenge test.
PURPOSE: Standard dosages of fluoropyrimidine chemotherapy result in severe toxicity in a substantial proportion of patients, however, routine pre-therapeutic toxicity prediction remains uncommon. A thymine (THY) challenge test can discriminate risk of severe gastrointestinal toxicity in patients receiving fluoropyrimidine monotherapy. We aimed to measure endogenous plasma uracil (U) and its ratio to dihydrouracil (DHU), and assess the performance of these parameters compared with the THY challenge test to evaluate risk of severe toxicity. METHODS: Plasma samples, previously collected from 37 patients receiving 5-fluorouracil (5-FU) or capecitabine monotherapy for a THY challenge test (ACTRN12615000586516; retrospectively registered), were assessed for endogenous plasma concentrations of U and DHU using a validated LC-MS/MS method. Renal function was estimated from blood creatinine, and patients with ≥ grade 3 toxicity (CTCAE v4.0) were classified as cases. RESULTS: There were no differences in median endogenous U plasma concentrations or U/DHU ratios between severe toxicity cases and non-cases. Significant differences between cases and non-cases were noted when these measures were normalised to the estimated renal function (CrCL), Unorm p = 0.0004; U/DHUnorm p = 0.0083. These two parameters had a sensitivity of 29%, compared with 57% for the THY challenge test in the same patients. Genotyping for clinically relevant DPYD variants was inferior to either of these pyrimidine phenotyping tests (sensitivity of 14%). CONCLUSIONS: The endogenous uracil-based parameters, adjusted to CrCL, were more predictive of increased risk of severe fluoropyrimidine toxicity than DPYD genotyping. However, endogenous U measurement detected fewer cases of severe toxicity than the THY challenge test.
Authors: A B van Kuilenburg; E W Muller; J Haasjes; R Meinsma; L Zoetekouw; H R Waterham; F Baas; D J Richel; A H van Gennip Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: John A Duley; Ming Ni; Catherine Shannon; Ross L Norris; Leslie Sheffield; David Cowley; Marion Harris; André B P van Kuilenburg; Nuala Helsby; Rani George; Bruce G Charles Journal: Ther Drug Monit Date: 2018-08 Impact factor: 3.681
Authors: Carin A T C Lunenburg; Linda M Henricks; Henk-Jan Guchelaar; Jesse J Swen; Maarten J Deenen; Jan H M Schellens; Hans Gelderblom Journal: Eur J Cancer Date: 2015-12-21 Impact factor: 9.162
Authors: M C van Staveren; H Jan Guchelaar; A B P van Kuilenburg; H Gelderblom; J G Maring Journal: Pharmacogenomics J Date: 2013-07-16 Impact factor: 3.550
Authors: Nuala A Helsby; John Duley; Kathryn E Burns; Claire Bonnet; Soo Hee Jeong; Elliott Brenman; Paula Barlow; Katrina Sharples; David Porter; Michael Findlay Journal: Br J Clin Pharmacol Date: 2019-12-12 Impact factor: 4.335
Authors: J G Maring; A B P van Kuilenburg; J Haasjes; H Piersma; H J M Groen; D R A Uges; A H Van Gennip; E G E De Vries Journal: Br J Cancer Date: 2002-04-08 Impact factor: 7.640
Authors: Dan Rosmarin; Claire Palles; David Church; Enric Domingo; Angela Jones; Elaine Johnstone; Haitao Wang; Sharon Love; Patrick Julier; Claire Scudder; George Nicholson; Anna Gonzalez-Neira; Miguel Martin; Daniel Sargent; Erin Green; Howard McLeod; Ulrich M Zanger; Matthias Schwab; Michael Braun; Matthew Seymour; Lindsay Thompson; Benjamin Lacas; Valérie Boige; Nuria Ribelles; Shoaib Afzal; Henrik Enghusen; Søren Astrup Jensen; Marie-Christine Etienne-Grimaldi; Gérard Milano; Mia Wadelius; Bengt Glimelius; Hans Garmo; Milena Gusella; Thierry Lecomte; Pierre Laurent-Puig; Eva Martinez-Balibrea; Rohini Sharma; Jesus Garcia-Foncillas; Zdenek Kleibl; Alain Morel; Jean-Pierre Pignon; Rachel Midgley; David Kerr; Ian Tomlinson Journal: J Clin Oncol Date: 2014-03-03 Impact factor: 50.717
Authors: Linda M Henricks; Bart A W Jacobs; Didier Meulendijks; Dick Pluim; Daan van den Broek; Niels de Vries; Hilde Rosing; Jos H Beijnen; Alwin D R Huitema; Henk-Jan Guchelaar; Annemieke Cats; Jan H M Schellens Journal: Br J Clin Pharmacol Date: 2018-09-25 Impact factor: 4.335